Filippo Banchini1, Gaetano Maria Cattaneo2, Patrizio Capelli2. 1. Department of General Surgery, Guglielmo da Saliceto Hospital, Piacenza, Italy. filippobanchini@virgilio.it. 2. Department of General Surgery, Guglielmo da Saliceto Hospital, Piacenza, Italy.
Abstract
BACKGROUND: SARS-CoV-2 infection has spread worldwide, and the pathogenic mechanism is still under investigation. The presence of a huge inflammatory response, defined as "cytokine storm," is being studied in order to understand what might be the prognostic factors implicated in the progression of the infection, with ferritin being one of such markers. The role of ferritin as a marker of inflammation is already known, and whether it changes differently between COVID and non-COVID patients still remains unclear. The aim of this retrospective analysis is to understand whether the inflammatory process in these two types is different. METHODS: In this retrospective analysis, we compared 17 patients affected by SARS-CoV-2, who had been admitted between February and April 2020 (group A) along with 30 patients admitted for acute surgical disease with SARS-CoV-2 negative swab (group B). A further subgroup of Covid negative patients with leukocytosis was compared to group A. RESULTS: In group A, the median (interquartile range) serum ferritin was 674 (1284) ng/mL, and it was double the cutoff (300 ng/mL) in 9 out of 17 (52%). The median (IQR) value of ferritin level in the total blood samples of group B was 231, and in the subgroup with leucocytosis, 149 (145). Group A showed a significantly higher ferritin median level compared to the entire group B (two-tailed Mann-Whitney test, p < 0.0001) as well as to the subgroup with leucocytosis (p < 0.0014). CONCLUSIONS: The role of iron metabolism appears to be directly involved in COVID infection. On the other hand, in the acute inflammation of patients admitted for surgery, and probably in other common phlogistic processes, iron modifications appear to be self-limited. However, our finding suggests the use of ferritin as a marker for COVID infection.
BACKGROUND:SARS-CoV-2 infection has spread worldwide, and the pathogenic mechanism is still under investigation. The presence of a huge inflammatory response, defined as "cytokine storm," is being studied in order to understand what might be the prognostic factors implicated in the progression of the infection, with ferritin being one of such markers. The role of ferritin as a marker of inflammation is already known, and whether it changes differently between COVID and non-COVIDpatients still remains unclear. The aim of this retrospective analysis is to understand whether the inflammatory process in these two types is different. METHODS: In this retrospective analysis, we compared 17 patients affected by SARS-CoV-2, who had been admitted between February and April 2020 (group A) along with 30 patients admitted for acute surgical disease with SARS-CoV-2 negative swab (group B). A further subgroup of Covid negativepatients with leukocytosis was compared to group A. RESULTS: In group A, the median (interquartile range) serum ferritin was 674 (1284) ng/mL, and it was double the cutoff (300 ng/mL) in 9 out of 17 (52%). The median (IQR) value of ferritin level in the total blood samples of group B was 231, and in the subgroup with leucocytosis, 149 (145). Group A showed a significantly higher ferritin median level compared to the entire group B (two-tailed Mann-Whitney test, p < 0.0001) as well as to the subgroup with leucocytosis (p < 0.0014). CONCLUSIONS: The role of iron metabolism appears to be directly involved in COVID infection. On the other hand, in the acute inflammation of patients admitted for surgery, and probably in other common phlogistic processes, iron modifications appear to be self-limited. However, our finding suggests the use of ferritin as a marker for COVID infection.
Authors: Mitchell M Levy; Mitchell P Fink; John C Marshall; Edward Abraham; Derek Angus; Deborah Cook; Jonathan Cohen; Steven M Opal; Jean-Louis Vincent; Graham Ramsay Journal: Crit Care Med Date: 2003-04 Impact factor: 7.598
Authors: Yi Jiang; Feng-Quan Jiang; Fang Kong; Meng-Meng An; Bei-Bei Jin; Da Cao; Ping Gong Journal: Ann Intensive Care Date: 2019-06-10 Impact factor: 6.925
Authors: Waleed Alhazzani; Morten Hylander Møller; Yaseen M Arabi; Mark Loeb; Michelle Ng Gong; Eddy Fan; Simon Oczkowski; Mitchell M Levy; Lennie Derde; Amy Dzierba; Bin Du; Michael Aboodi; Hannah Wunsch; Maurizio Cecconi; Younsuck Koh; Daniel S Chertow; Kathryn Maitland; Fayez Alshamsi; Emilie Belley-Cote; Massimiliano Greco; Matthew Laundy; Jill S Morgan; Jozef Kesecioglu; Allison McGeer; Leonard Mermel; Manoj J Mammen; Paul E Alexander; Amy Arrington; John E Centofanti; Giuseppe Citerio; Bandar Baw; Ziad A Memish; Naomi Hammond; Frederick G Hayden; Laura Evans; Andrew Rhodes Journal: Intensive Care Med Date: 2020-03-28 Impact factor: 17.440
Authors: Anna Brandtner; Piotr Tymoszuk; Manfred Nairz; Georg F Lehner; Gernot Fritsche; Anja Vales; Andreas Falkner; Harald Schennach; Igor Theurl; Michael Joannidis; Günter Weiss; Christa Pfeifhofer-Obermair Journal: J Intensive Care Date: 2020-10-01
Authors: Thomas Sonnweber; Philipp Grubwieser; Sabina Sahanic; Anna Katharina Böhm; Alex Pizzini; Anna Luger; Christoph Schwabl; Sabine Koppelstätter; Katharina Kurz; Bernhard Puchner; Barbara Sperner-Unterweger; Katharina Hüfner; Ewald Wöll; Manfred Nairz; Gerlig Widmann; Ivan Tancevski; Judith Löffler-Ragg; Günter Weiss Journal: Metabolites Date: 2022-06-14
Authors: Vidyashree S Hulkoti; Sourya Acharya; Sunil Kumar; Dhruv Talwar; Shivam Khanna; Akhilesh Annadatha; Sparsh Madaan; Vinay Verma; V V S S Sagar Journal: J Family Med Prim Care Date: 2022-05-14
Authors: Lorena Franco-Martínez; José J Cerón; María R Vicente-Romero; Enrique Bernal; Alberto Torres Cantero; Fernando Tecles; Cristina Sánchez Resalt; Mónica Martínez; Asta Tvarijonaviciute; Silvia Martínez-Subiela Journal: Int J Environ Res Public Health Date: 2021-12-21 Impact factor: 3.390